Eli Lilly and Company
Stock Forecast, Prediction & Price Target
Eli Lilly and Company (LLY) stock Price Target by analysts
Eli Lilly and Company (LLY) stock Price Target by analysts
Average Price Target
$1,000
Potential upside: 43.16%
Eli Lilly and Company price prediction
What is Eli Lilly and Company stock analysts` prediction?
Eli Lilly and Company stock forecast: Based on 2 Wall Street analysts` predicted price targets for Eli Lilly and Company in the last 3 months, the avarage price target is $1,000, with a high forecast of $NaN. The average price target represents a 43.16% change from the last price of $698.5.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Eli Lilly and Company stock Price Target by analysts
Full breakdown of analysts given Eli Lilly and Company price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Evan David Seigerman BMO Capital | 25% 1/4 | 11 months ago | $1,010 44.59% upside | $829.74 | StreetInsider | Previous targets (3) |
Andrew Berens Leerink Partners | 0% 0/1 | 11 months ago | $990 41.73% upside | $932.06 | StreetInsider | Previous targets (0) |
Peter Verdult Citigroup | 0% 0/1 | about 1 year ago | $1,060 51.75% upside | $935.02 | StreetInsider | Previous targets (0) |
Terence Flynn Morgan Stanley | 40% 2/5 | about 1 year ago | $1,106 58.33% upside | $957.51 | StreetInsider | Previous targets (4) |
Kerry Holford Berenberg Bank | 0% 0/2 | about 1 year ago | $1,050 50.32% upside | $908.05 | TheFly | Previous targets (1) |
James Shin Deutsche Bank | 50% 1/2 | about 1 year ago | $1,025 46.74% upside | $891.68 | TheFly | Previous targets (1) |
Mohit Bansal Wells Fargo | 50% 2/4 | about 1 year ago | $1,000 43.16% upside | $845.31 | TheFly | Previous targets (3) |
Geoff Meacham Bank of America Securities | 50% 1/2 | about 1 year ago | $1,150 64.63% upside | $845.31 | StreetInsider | Previous targets (1) |
Chris Shibutani Goldman Sachs | 33.33% 1/3 | about 1 year ago | $856 22.54% upside | $891.68 | Benzinga | Previous targets (2) |
Evan David Seigerman BMO Capital | 25% 1/4 | about 1 year ago | $1,101 57.62% upside | $845.31 | StreetInsider | Previous targets (3) |
Terence Flynn Morgan Stanley | 40% 2/5 | about 1 year ago | $1,083 55.04% upside | $939.78 | TheFly | Previous targets (4) |
Kerry Holford Berenberg Bank | 0% 0/2 | about 1 year ago | $1,000 43.16% upside | $939.78 | TheFly | Previous targets (1) |
Terence Flynn Morgan Stanley | 40% 2/5 | about 1 year ago | $1,023 46.45% upside | $906.15 | TheFly | Previous targets (4) |
Akash Tewari Jefferies | 0% 0/4 | about 1 year ago | $1,015 45.31% upside | $883.88 | TheFly | Previous targets (3) |
Akash Tewari Jefferies | 0% 0/4 | over 1 year ago | $957 37.00% upside | $837.29 | StreetInsider | Previous targets (3) |
Geoff Meacham Barclays | 0% 0/1 | over 1 year ago | $913 30.70% upside | $820.34 | StreetInsider | Previous targets (0) |
Chris Shibutani Goldman Sachs | 33.33% 1/3 | over 1 year ago | $785 12.38% upside | $818.41 | Benzinga | Previous targets (2) |
Akash Tewari Jefferies | 0% 0/4 | over 1 year ago | $925 32.42% upside | $805.06 | StreetInsider | Previous targets (3) |
Akash Tewari Jefferies | 0% 0/4 | over 1 year ago | $915 30.99% upside | $770 | StreetInsider | Previous targets (3) |
Mohit Bansal Wells Fargo | 50% 2/4 | over 1 year ago | $875 25.26% upside | $771.12 | StreetInsider | Previous targets (3) |
David Toung Argus Research | 50% 1/2 | over 1 year ago | $840 20.25% upside | $757.7 | StreetInsider | Previous targets (1) |
Evan Seigerman BMO Capital | 0% 0/1 | over 1 year ago | $1,001 43.30% upside | $781.1 | TheFly | Previous targets (0) |
Louise Chen Cantor Fitzgerald | 66.67% 2/3 | over 1 year ago | $885 26.70% upside | $781.1 | StreetInsider | Previous targets (2) |
Evan David Seigerman BMO Capital | 25% 1/4 | over 1 year ago | $900 28.84% upside | $748.4 | StreetInsider | Previous targets (3) |
James Shin Deutsche Bank | 50% 1/2 | over 1 year ago | $535 -23.40% downside | $706.2 | Benzinga | Previous targets (1) |
Andrew Baum Citigroup | 100% 2/2 | over 1 year ago | $675 -3.36% downside | $581.51 | Benzinga | Previous targets (1) |
David Phung Morgan Stanley | 100% 1/1 | almost 2 years ago | $673 -3.65% downside | $601.49 | Benzinga | Previous targets (0) |
Louise Chen Cantor Fitzgerald | 66.67% 2/3 | about 2 years ago | $630 -9.80% downside | $526.4 | Benzinga | Previous targets (2) |
Terence Flynn Morgan Stanley | 40% 2/5 | about 2 years ago | $617 -11.66% downside | $526.4 | Benzinga | Previous targets (4) |
Unknown Morgan Stanley | N/A | over 2 years ago | $455 -34.86% downside | $330.7 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $360 -48.46% downside | $337.54 | Benzinga | N/A |
Unknown Barclays | N/A | over 2 years ago | $400 -42.73% downside | $366.71 | Benzinga | N/A |
Cowen Cowen Cowen & Co. | 100% 1/1 | almost 3 years ago | $430 -38.43% downside | $359.87 | Pulse 2.0 | Previous targets (0) |
Unknown Leerink Partners | N/A | almost 3 years ago | $410 -41.30% downside | $360.01 | Benzinga | N/A |
Unknown UBS | N/A | almost 3 years ago | $420 -39.87% downside | $363.5 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $440 -37.00% downside | $361.99 | Benzinga | N/A |
Unknown Wells Fargo | N/A | almost 3 years ago | $375 -46.31% downside | $370.1 | Benzinga | N/A |
Unknown Guggenheim | N/A | almost 3 years ago | $401 -42.59% downside | $372.39 | Benzinga | N/A |
Unknown Credit Suisse | N/A | almost 3 years ago | $400 -42.73% downside | $367.74 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $446 -36.14% downside | $368.01 | Benzinga | N/A |
Unknown Cowen & Co. | N/A | almost 3 years ago | $430 -38.43% downside | $372.51 | Benzinga | N/A |
Unknown Credit Suisse | N/A | almost 3 years ago | $395 -43.45% downside | $360.77 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $436 -37.58% downside | $354.66 | Benzinga | N/A |
Colin Bristow Bristow UBS | 100% 1/1 | almost 3 years ago | $336 -51.89% downside | $323.35 | Pulse 2.0 | Previous targets (0) |
Navin Jacob UBS | 100% 3/3 | almost 3 years ago | $363 -48.03% downside | $296.48 | StreetInsider | Previous targets (2) |
Unknown Morgan Stanley | N/A | about 3 years ago | $412 -41.01% downside | $310.91 | Benzinga | N/A |
Unknown BMO Capital | N/A | about 3 years ago | $396 -43.30% downside | $306.39 | Benzinga | N/A |
Evan Seigerman Loop Capital Markets | 100% 1/1 | about 3 years ago | $7.9 -98.86% downside | $304.82 | Investing | Previous targets (0) |
Unknown Morgan Stanley | N/A | about 3 years ago | $395 -43.45% downside | $327.95 | Benzinga | N/A |
Unknown Barclays | N/A | about 3 years ago | $355 -49.17% downside | $330.15 | Benzinga | N/A |
Eli Lilly and Company Financial Estimates
Eli Lilly and Company Revenue Estimates
Eli Lilly and Company EBITDA Estimates
Eli Lilly and Company Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $28.31B N/A | $28.54B 0.78% | $34.12B 19.56% | Avg: $52.68B Low: $50.43B High: $55.79B avg. 54.37% | Avg: $62.25B Low: $59.50B High: $65.36B avg. 18.17% | Avg: $68.82B Low: $65.77B High: $72.26B avg. 10.54% | Avg: $79.63B Low: $76.11B High: $83.61B avg. 15.71% |
Net Income
% change YoY
| $5.58B N/A | $6.24B 11.87% | $5.24B -16.08% | Avg: $16.63B Low: $15.07B High: $18.12B avg. 217.36% | Avg: $21.43B Low: $17.69B High: $24.91B avg. 28.89% | Avg: $26.07B Low: $24.57B High: $27.76B avg. 21.62% | Avg: $31.91B Low: $30.08B High: $33.99B avg. 22.41% |
EBITDA
% change YoY
| $8.73B N/A | $9.43B 7.94% | $8.56B -9.17% | Avg: $16.97B Low: $16.25B High: $17.98B avg. 98.16% | Avg: $20.06B Low: $19.17B High: $21.06B avg. 18.17% | Avg: $22.17B Low: $21.19B High: $23.28B avg. 10.54% | Avg: $25.66B Low: $24.53B High: $26.94B avg. 15.71% |
EPS
% change YoY
| $6.15 N/A | $6.93 12.68% | $5.8 -16.30% | Avg: $18.68 Low: $16.69 High: $20.07 avg. 222.05% | Avg: $24 Low: $19.59 High: $27.58 avg. 28.48% | Avg: $28.87 Low: $27.21 High: $30.74 avg. 20.27% | Avg: $35.34 Low: $33.31 High: $37.63 avg. 22.41% |
Operating Expenses
% change YoY
| $13.45B N/A | $13.63B 1.29% | $16.71B 22.63% | Avg: $12.61B Low: $12.07B High: $13.36B avg. -24.51% | Avg: $14.91B Low: $14.25B High: $15.65B avg. 18.17% | Avg: $16.48B Low: $15.75B High: $17.30B avg. 10.54% | Avg: $19.07B Low: $18.23B High: $20.02B avg. 15.71% |
FAQ
What is Eli Lilly and Company stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 72.57% in 2025-2028.
We have gathered data from 14 analysts. Their low estimate is 15.07B, average is 16.63B and high is 18.12B.
What is Eli Lilly and Company stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 24.70% in 2025-2028.
We have gathered data from 19 analysts. Their low revenue estimate is $50.43B, average is $52.68B and high is $55.79B.
What is Eli Lilly and Company stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 73.30% in 2025-2028.
We have gathered data from 14 analysts. Their low earnings per share estimate is $16.69, average is $18.68 and high is $20.07.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Eli Lilly and Company stock. The most successful analyst is Evan David Seigerman whose win rate is 25%. He has correctly predicted 1/4 price targets.